Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, Multicenter, Open-label Study of S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

NCT05101070 is registered in ClinicalTrials.gov with Shionogi as lead sponsor.

NCT NCT05101070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05101070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, Multicenter, Open-label Study of S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Shionogi
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 30, 2022
Completion date
May 31, 2028
Enrollment
282 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors